Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative antifungal and antiviral medicines. The company's portfolio includes therapies aimed at addressing serious infectious diseases, with an emphasis on immunocompromised and immunosuppressed patient populations. Cidara leverages novel delivery platforms and targeted approaches to improve treatment outcomes in difficult-to-treat infections.
Company News
Cidara Therapeutics granted non-qualified stock options and restricted stock units totaling 12,100 shares to two new employees under its 2020 Inducement Incentive Plan, with stock options priced at $48.71 per share and vesting over four years.
Cidara Therapeutics announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price of $44.00 per share, raising $350 million in gross proceeds.
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.66% and 26.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.